Research Triangle Park-based SCYNEXIS received a payment for meeting certain milestones in its multi-year research collaboration with Merial
SCYNEXIS entered the agreement in 2005 to support Merial's animal health discovery efforts. Dr. Yves Ribeill, SCYNEXIS president and CEO, did not disclose the amount of the payment.
"Merial is excited about the continued success of our pharmaceutical discovery program and by the opportunity to continue working with SCYNEXIS to conduct further research regarding novel compounds that will be designed specifically to address animal health needs," said Dr. Peter Hanson, head of pharmaceutical R&D for Merial.